NASDAQ:OGIOrganiGram Stock Price, Forecast & News

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OGI shares have decreased by 9.3% and is now trading at $1.56. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for OrganiGram.

OrganiGram is scheduled to release its next quarterly earnings announcement on Monday, July 20th 2020. View our earnings forecast for OrganiGram.

OrganiGram Holdings Inc (NASDAQ:OGI) released its earnings results on Tuesday, April, 14th. The company reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.01. The company had revenue of $27.30 million for the quarter, compared to analyst estimates of $25.07 million. OrganiGram had a negative return on equity of 5.33% and a negative net margin of 45.14%. The firm's revenue was down 18.3% on a year-over-year basis. View OrganiGram's earnings history.

12 brokerages have issued twelve-month price objectives for OrganiGram's shares. Their forecasts range from $1.72 to $12.00. On average, they expect OrganiGram's share price to reach $6.46 in the next twelve months. This suggests a possible upside of 314.2% from the stock's current price. View analysts' price targets for OrganiGram.

Headlines about OGI stock have been trending negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. OrganiGram earned a news impact score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about OrganiGram.

Some companies that are related to OrganiGram include DiaMedica Therapeutics (DMCAF), Athenex (ATNX), Arcus Biosciences (RCUS), Aimmune Therapeutics (AIMT), Phibro Animal Health (PAHC), BioXcel Therapeutics (BTAI), Amphastar Pharmaceuticals (AMPH), Legend Biotech (PLRX), Enanta Pharmaceuticals (ENTA), Rhythm Pharmaceuticals (RYTM), Nabriva Therapeutics (NBRV), Akero Therapeutics (AKRO), Arcturus Therapeutics (ARCT), Phathom Pharmaceuticals (PHAT) and Retrophin (RTRX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), KushCo (KSHB), Aphria (APHA), Auxly Cannabis Group (CBWTF), Charlotte's Web (CWBHF), Innovative Industrial Properties (IIPR), NVIDIA (NVDA) and Alibaba Group (BABA).

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OGI stock can currently be purchased for approximately $1.56.

OrganiGram has a market capitalization of $274.10 million and generates $61.27 million in revenue each year. The company earns $-7,200,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. OrganiGram employs 615 workers across the globe.

The official website for OrganiGram is www.organigram.ca.

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.